Month in Review
February emphasized treatment strategy and trial design rather than new drug approvals. Data in advanced NSCLC explored de-escalation of immunotherapy and adaptive testing of novel IO combinations, while observational evidence suggested infusion timing may influence outcomes. In resectable disease, historical multimodality data and new pragmatic trial frameworks highlighted how sequencing and operational design shape interpretation of survival endpoints. In parallel, prospective EGFR-mutant data reinforced systemic-first approaches in active brain metastases and underscored the prognostic relevance of mutation subtype and baseline ctDNA. Overall, the month centered on optimization of duration, timing, sequencing, and trial efficiency, rather than new mechanisms.
Core Studies
Immunotherapy
Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients with Advanced NSCLC (DICIPLE)
Journal of Thoracic Oncology
Study: Randomized phase III in stage IV NSCLC. All patients received nivolumab + ipilimumab for 6 months; those with disease control were randomized to continue treatment versus stop-and-go (resume at progression).
Key data: Randomized: continue (n=76); stop (n=78). PFS (PP population) HR 0.76 (95% CI 0.54–1.08). PFS (ITT) HR 0.81 (95% CI 0.58–1.13).
Why it matters: Tests whether fixed-duration nivolumab/ipilimumab preserves efficacy. No statistically significant PFS difference was observed. Interesting for de-escalation strategies.
Clinical context & caveats: Trial stopped early (reimbursement); limited power. French accrual. No OS advantage demonstrated.
Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology in Patients with Advanced NSCLC (FRACTION-Lung)
ESMO Open
Study: Open-label, multi-track, noncomparative phase II platform trial evaluating nivolumab alone or combined with dasatinib, ipilimumab, relatlimab, or linrodostat.
Key data: Highest ORR was achieved with Nivolumab + Ipilimumab (25.0%). Grade 3–4 TRAEs 4–20%.
Why it matters: Illustrates adaptive platform testing of IO combinations. Limited efficacy signals overall.
Clinical context & caveats: Small per-arm N; noncomparative; no active CNS metastases allowed; discontinued early. Older study with limited clinical value, but the adaptive study design has potential for future trial designs.
Morning Immune Checkpoint Inhibitor Infusion is Associated with Improved Survival in Metastatic NSCLC Undergoing Immunochemotherapy (Time-of-Day Study)
Nature Medicine
Study: Retrospective cohort (n=127) of metastatic NSCLC treated with first-line immunochemotherapy. Early infusion (<15:00) vs late (≥15:00).
Key data: OS HR 0.79 (p=0.02). PFS and ORR were not statistically significant.
Why it matters: Suggests possible circadian modulation of IO efficacy.
Clinical context & caveats: Retrospective; single-center; modest effect size; non-randomized; hypothesis-generating.
Stage III/Multimodality
Phase III Trial Comparing Surgery to Definitive Chemoradiotherapy Boost in Patients with Stage IIIA(N2) and Selected IIIB NSCLC After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
European Journal of Cancer
Study: Randomized phase III comparing surgery vs CRT boost after induction chemotherapy + concurrent CRT.
Key data: OS HR 0.79 (p=0.15); 5-year OS 44% vs 40%.
Why it matters: No statistically confirmed survival advantage for adding surgery in this selected population.
Clinical context & caveats: Pre-immunotherapy era; highly selected patients; modern consolidation IO not included. Could serve as a baseline for comparison of contemporary studies.
Other Notable Publications
Targeted Therapy
Upfront Treatment with Osimertinib in Lung Cancer Patients with and without Active Brain Metastases, and the Role of ctDNA as a biomarker (FIOL)
Lung Cancer
Study: Single-arm phase II of first-line osimertinib in EGFR-mutant advanced NSCLC including active/symptomatic brain metastases (N=100; 46 active BM).
Key data: ORR 72.0% (95% CI 62.1–80.5); 69.6% (active BM) vs 74.1% (no active BM) (p=0.66). mOS 32.8 months. Baseline ctDNA absence associated with longer PFS (27.3 vs 14.5 months, p=0.042) and OS (NR vs 27.6 months, p=0.028). Intracranial ORR 81.8% in measurable BM. EGFR subtype associated with PFS (p=0.010) and OS (p=0.002).
Why it matters: Supports systemic-first strategy in selected active BM with structured early monitoring; ctDNA and mutation subtype refine prognosis.
Clinical context & caveats: Single-arm; small biomarker subgroups; intensive MRI schedule may limit generalizability.
Trial Protocol
A National Clinical Trial Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials (PROSPECT-LUNG)
Journal of Thoracic Oncology
Study: Operational trial-design paper focused on reducing clinical trial burden.
Key data: Protocol length reduced 88 → 30 pages (–65%). Estimated workload reduced 210 → 36.5 hours per patient.
Why it matters: Demonstrates a scalable model for reducing trial complexity; relevant for real-world enrollment and feasibility.
Clinical context & caveats: No efficacy data; design/operations study.
Expert Takeaways
Fixed-duration IO remains unproven in advanced disease, but opens doors for de-escalation strategies.
Stage III surgical intensification did not demonstrate survival superiority.
Circadian biology may influence IO outcomes, but evidence is observational.
Trial simplification (PROSPECT) may be as impactful operationally as new drugs biologically.
Notes on Generalizability & Bias Signals
FIOL used structured early CNS imaging (week 4 MRI in active BM), which may improve detection and management compared with routine practice.
Several trials are pre-immunotherapy-era.
FRACTION small-arm noncomparative design limits inference.
Time-of-day study subject to scheduling and residual confounding bias.
Disclaimer: Publication dates refer to online-first publication.
If you found this useful, subscribe to receive next month’s synthesis.
Know a colleague who would benefit? Forward this issue.
Refer a colleague